Human Vaccines & Immunotherapeutics
Volume 16, 2020 - Issue 6
Commentary
Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
, 
&
Peter J. Hoteza Texas Children’s Hospital Center for Vaccine Development, Departments of Pediatrics, Baylor College of Medicine, Houston, TX, USA;b National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA;c Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX, USAhttps://orcid.org/0000-0001-8770-1042
https://orcid.org/0000-0001-8770-1042 & 